Rocklatan, an ophthalmic solution containing netarsudil, is used to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension [1]. Clinical trials have evaluated its efficacy and safety [2].
How effective is Rocklatan in lowering eye pressure?
Clinical studies have demonstrated Rocklatan's ability to significantly reduce IOP. In Phase 3 trials, once-daily administration of Rocklatan resulted in IOP reductions comparable to timolol, a commonly prescribed beta-blocker [2][3]. For instance, in one trial, Rocklatan achieved mean IOP reductions of 5.7 mmHg at week 4 and 5.4 mmHg at week 12, while timolol achieved 5.4 mmHg and 5.2 mmHg respectively at the same time points [2]. Another Phase 3 trial showed Rocklatan achieved a mean IOP reduction of 5.0 mmHg at week 12, compared to 3.6 mmHg for vehicle [3].
What are the potential side effects of Rocklatan?
The most common adverse reaction reported in clinical trials for Rocklatan was conjunctival hyperemia, or redness of the eye, occurring in approximately 50% of patients [1][2][3]. Other reported side effects include conjunctival emphysema, corneal verticillata, and instances of anterior uveitis or iritis [1]. Most side effects were mild to moderate in severity and resolved on their own [2].
How does Rocklatan work to lower eye pressure?
Rocklatan's mechanism of action involves targeting multiple pathways. It is a rho kinase inhibitor, which helps to increase the outflow of aqueous humor through the trabecular meshwork [1][4]. This mechanism is distinct from many other glaucoma medications [4].
When did Rocklatan receive FDA approval?
Rocklatan received FDA approval in March 2019 [1].
What is the difference between Rocklatan and other glaucoma treatments?
Rocklatan's unique mechanism as a rho kinase inhibitor differentiates it from other classes of glaucoma medications, such as prostaglandin analogs, beta-blockers, and alpha-adrenergic agonists [4]. This allows it to potentially offer an alternative for patients who do not achieve adequate IOP control with existing therapies or who experience intolerable side effects [4].
Where can I find more information on Rocklatan's clinical data?
Detailed clinical trial data and information on Rocklatan can be found on the DrugPatentWatch.com website [1].